<DOC>
	<DOCNO>NCT02784275</DOCNO>
	<brief_summary>This double-blind , randomize , placebo-controlled , parallel-group comparison study evaluate efficacy safety Cyclo-Z treatment subject obese type 2 diabetes . The study consist 3 phase : - Screening phase ( 2 week ) - Treatment phase ( 12 week ) - Follow-up phase ( 2 week ) Following 2-week screening period , subject meet inclusion exclusion criterion randomly assign one follow treatment arm : - Dose A : Cyclo-Z contain 23 mg zinc plus 3 mg CHP - 16 subject - Dose B : Cyclo-Z contain 23 mg zinc plus 9 mg CHP - 16 subject - Dose C : Cyclo-Z contain 23 mg zinc plus 15 mg CHP - 16 subject - Dose D : Placebo - 16 subject The assigned dose orally administered subject day bedtime 12 consecutive week . After randomization Week 0 ( Visit 2 ) , subject visit respective trial site Weeks 2 , 4 , 6 , 8 , 10 , 12 , 14 ( Visits 3 , 4 , 5 , 6 , 7 , 8 , 9 ) .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Cyclo-Z Patients With Obese Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>1 . Males female age 18 old . 2 . Subjects diagnose type 2 diabetes mellitus accord American Diabetes Association ( ADA ) criterion . 3 . Subjects treat stable dos insulin and/or hypoglycemic agent ( ) type 2 diabetes mellitus least 2 month prior randomization . 4 . Subjects whose fast blood glucose level reasonably stable least 2 month prior randomization 2week screening period . 5 . Subjects Hemoglobin A1c level 7.5 10.0 % Screening . 6 . Subjects whose BMI 30 . 7 . Subjects give write informed consent . 1 . Subjects DMrelated endorgan damage . 2 . Subjects history diabetic ketoacidosis hyperosmolar nonketotic coma . 3 . Subjects disease likely limit life span and/or increase risk intervention : Carotid Bmode ultrasound test result indicate clinically significant stenosis common carotid artery require intervention angioplasty resection . Cancer treatment past 5 year , exception cancer cure , carry good prognosis . Infectious disease : HIV positivity , active tuberculosis , pneumonia . 4 . Subjects follow condition related cardiovascular disease : Hospitalization treatment heart disease past 12 month . New York Heart Association Functional Class &gt; 2 . Left Bundle branch block ECG Screening . Third degree atrioventricular block ECG Screening . Uncontrolled hypertension average systolic blood pressure &gt; 160 mmHg diastolic blood pressure &gt; 95 mmHg Screening Baseline . Pulse rate &gt; 95 beat per minute Screening Baseline . Stroke transient ischemic attack past 12 month . 5 . Subjects follow condition related gastrointestinal disease : Chronic hepatitis cirrhosis . Episode alcoholic hepatitis alcoholic pancreatitis past 2 month . Inflammatory bowel disease require treatment past 12 month . Significant abdominal surgery ( e.g. , gastrectomy , gastric bypass ) past 2 month . 6 . Subjects serum creatinine &gt; 1.5 mg/dL male &gt; 1.4 mg/dL female . 7 . Subjects chronic obstructive airway disease asthma require daily therapy home use oxygen . 8 . Subjects hematocrit &lt; 36.0 % male &lt; 33.0 % female . 9 . Subjects follow condition behavior likely affect conduct study : Weight loss &gt; 10 % past 6 month . Unable walk without assisted device . Major psychiatric disorder would impede conduct research . Excessive alcohol intake ( i.e. , 2 drinks/day ) . 10 . Subjects take follow medication : Psychoactive agent monoamine oxidase inhibitor antidepressant ( e.g. , lithium , Prozac , Zoloft , Serzone , Paxil , Effexor ) . Any medication may pose harm subject . 11 . Female subject positive serum pregnancy test Screening , plan pregnancy study period , breast feeding . 12 . Female subject n't meet following criterion : Surgically sterile ( i.e. , bilateral tubal ligation , hysterectomy , bilateral oophorectomy ) least 6 month randomization . Postmenopausal least 12 month prior Screening . If sexually active , use oral contraceptive , double barrier contraception ( e.g. , condom spermicide ) , intrauterine device , method approve Sponsor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>